Info

SIGA Technologies, Inc. (SIGA) is a biotechnology company that discovers, develops and commercializes anti-infectives for serious infectious diseases. The major focus of the Company's developmental and commercialization activities is on products for use in defense against biological warfare agents, such as smallpox and arenaviruses (hemorrhagic fevers). SIGA's lead product, ST-246, is an orally administered anti-viral drug that targets the smallpox virus. The Company's anti-viral programs are designed to prevent or limit the replication of the viral pathogen. SIGA's anti-infectives programs are aimed at the problem of drug resistance.(Source: 10-K)